Published in

Public Library of Science, PLoS ONE, 10(11), p. e0164076, 2016

DOI: 10.1371/journal.pone.0164076

Links

Tools

Export citation

Search in Google Scholar

Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry

Journal article published in 2016 by Sylvia Haas, Hugo ten Cate, H. T. Cate, Gabriele Accetta, Pantep Angchaisuksiri, Jean-Pierre Bassand, A. John Camm, Ramon Corbalan, Harald Darius, David A. Fitzmaurice, Samuel Z. Goldhaber, Shinya Goto, Barry Jacobson, Gloria Kayani, Lorenzo G. Mantovani and other authors.
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Green circle
Postprint: archiving allowed
Green circle
Published version: archiving allowed
Data provided by SHERPA/RoMEO

Abstract

Aims Vitamin K antagonists (VKAs) need to be individually dosed. International guidelines recommend a target range of international normalised ratio (INR) of 2.0–3.0 for stroke prevention in atrial fibrillation (AF). We analysed the time in this therapeutic range (TTR) of VKA-treated patients with newly diagnosed AF in the ongoing, global, observational registry GARFIELD-AF. Taking TTR as a measure of the quality of patient management, we analysed its relationship with 1-year outcomes, including stroke/systemic embolism (SE), major bleeding, and all-cause mortality. Methods and Results: TTR was calculated for 9934 patients using 136,082 INR measurements during 1-year follow-up. The mean TTR was 55.0%; values were similar for different VKAs. 5851 (58.9%) patients had TTR